Treatment Paradigms in AMD Management -

Name: Treatment Paradigms in AMD Management
Uploaded: 2017-05-01T08:00:00+00:00
Duration: 59 min 35 s
Description: The increasing number of new patients with CNV and neovascular AMD presenting to retina specialists on top of the already large and active treatment popula

Media formats available:

Details

Presenters

Overview
The increasing number of new patients with CNV and neovascular AMD presenting to retina specialists on top of the already large and active treatment population has created a desire among clinicians to reduce treatment burden. Recent studies suggest that long-term treatment outcomes are not necessarily sustained over time. This could be a result of under treatment, disease progression, or even tachyphylaxis to the anti-VEGF drug. Until more is known about how neovascular AMD progresses and what the best treatment algorithms are, retina specialists will need to stay abreast of the latest study findings in order to continue to deliver the best patient care.Supported by an educational grant from Regeneron Pharmaceuticals.
Learning Objectives
Upon completion of this activity, participants will be better able to:
- Discuss the outcomes of pivotal studies in AMD, and how study results may differ from “real-world” dosing method
- Identify patient subtypes (eg. RAP lesion, pigment epithelial detachments, occult lesions) that will require long-term treatment and imaging evaluation.
- Develop a long term treatment plan for patients with AMD based on results from clinical trials and extension studies
- Compare the extended safety outcomes of anti-VEGF therapies as published in long term studies.
Accreditation
Accreditation and Designation Statement
ACCREDITATION STATEMENT
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA CREDIT DESIGNATION STATEMENT
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Faculty and Disclosures
DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
The following faculty members have the following financial relationships with commercial interests: •Lloyd Clark, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Bayer Pharmaceuticals; Genentech, Inc; Ohr Pharmaceutical, Inc.; Regeneron Pharmaceuticals, Inc.; and Santen Pharmaceutical Co., Ltd. Grant/Research Support: Allergan, Inc.; Genentech, Inc and Regeneron Pharmaceuticals, Inc. •Carl Regillo, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan, Inc.; Genentech, Inc; Iconic Therapeutics; and Notal Vision. Grant/Research Support: Alcon; Allergan, Inc.; Genentech, Inc; GlaxoSmithKline; Iconic Therapeutics; Novartis; and Regeneron Pharmaceuticals, Inc. Editorial Support Disclosure •Cheryl Cavanaugh, MS, Evolve Medical Education LLC and Michelle Dalton, Writer; have no real or apparent conflicts of interest to report. •Rishi P. Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Plc; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date: 05/01/2017
Expiration Date: 05/31/2018

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
CME/CE
VBS Fellows’ Foray 2026: Through the Looking Glass—Real-World Vitreoretinal Surgical Cases
Yewlin E. Chee, MD; Camila Ventura MD, PhD
1.50 credits
- Yewlin E. Chee, MD
- Camila Ventura MD, PhD
- Edward Wood, MD
- Tony Capone Jr, MD
- Katherine E. Talcott, MD
- Nassim Abreu, MD
1.50 credits
CME/CE In-Person & Virtual Event
Treating Outside the Box: New Pathways to Retinal Vascular Stability
July 17, 2026
Montreal
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
CME/CE Broadcast Replay
Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies
Deepak Sambhara, MD
1.00 credit
- Deepak Sambhara, MD
1.00 credit
Who Needs a TKI? Identifying the Right Candidates
Who Needs a TKI? Identifying the Right Candidates
MinuteCE®
Who Needs a TKI? Identifying the Right Candidates
Roger A. Goldberg, MD, MBA; Christina Y. Weng, MD, MBA, FASRS
0.75 program credits
- Roger A. Goldberg, MD, MBA
- Christina Y. Weng, MD, MBA, FASRS
0.75 program credits

Treatment Paradigms in AMD Management

Overview

Learning Objectives

Accreditation

Faculty and Disclosures

System Requirements

Publication Dates

Recommended

Title